Pacritinib or hydroxyurea for advanced CMML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether pacritinib works better than hydroxyurea for people with advanced proliferative chronic myelomonocytic leukemia (CMML). It may help if your white blood cell count is high and you have an enlarged spleen, severe symptoms, or low platelets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CMML-1 (a type of CMML with fewer than 10% blasts in your bone marrow and fewer than 5% in your blood).
- Your white blood cell count is 13 or higher (proliferative disease).
- Your disease has advanced features, like an enlarged spleen felt below your ribs, a total symptom score of 20 or more, or a low platelet count.
- You are able to do most daily activities on your own (ECOG 0-2).
- Your liver and kidney function are adequate, and blood counts meet minimum levels.
- You have not used a JAK inhibitor (like ruxolitinib) before for CMML.
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
This trial tests a combination of three drugs (pacritinib, venetoclax, and azacitidine) in people whose myeloproliferative neoplasm (MPN) has progressed to a faster-growing, more aggressive phase (accelerated or blast phase). The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Hear when a new Leukemia, Myelomonocytic, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.